TXG Trading Analysis - 10/30/2026 01:01 PM — TRU-SENTIMENT

TXG (10x Genomics Inc. Class A Common Stock) at $69.50. True Sentiment Bullish, delta 40-60 call 99% / put 1%, call $1,364,530 vs put $11,720. RSI 50.1.

TRU-SENTIMENT · DeltaNeutral

TXG Trading Analysis - 10/30/2026 01:01 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

TXG (10x Genomics Inc. Class A Common Stock) at $69.50. True Sentiment Bullish, delta 40-60 call 99% / put 1%, call $1,364,530 vs put $11,720. RSI 50.1.

Symbol
TXG
Price
$69.50
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-10-30 13:01:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From TXG_options_2026-10-30 data:

Call Dollar Volume: $1,364,530.00 (99.10%) Put Dollar Volume: $11,720.00 (0.90%) Total: $1,376,250.00

  • Call contracts: 2,385; Put contracts: 12 — extreme call skew.
  • Sentiment: Bullish
  • Pure directional conviction strongly favors calls (Delta 40-60 filtered).

Notable divergence: Technicals are neutral (RSI 50.09, no clear trend break), yet options flow is 99.1% call dollar volume. Option spread engine flagged: "Divergence detected between technical indicators and options sentiment."

Key Statistics: TXG

$69.26 -15.08%
52-Week Range
$12.34 - $102.81
Market Cap
$9.02B
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
1.72
Next Earnings
N/A
Avg Volume
$2.70M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

EPS (trailing 12 mo)$-0.59
Market cap$9.02B
Shares outstanding130.3M

Dividend

Dividend yield0.00%

Risk & range

Beta1.72
52-week low$12.34
52-week high$102.81
Historical volatility91.2%

Ownership & trading

Institutional ownership76.7%
Average daily volume4.0M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

Recent general-knowledge context for 10x Genomics (TXG) suggests the following themes that may frame the data below:

  • 10x Genomics has faced soft demand in its single-cell genomics instruments amid broader biotech funding pressure through 2026.
  • The company reported a continued net loss in its most recent fiscal year (FY ended Dec 2025), with EPS negative.
  • Product expansion in spatial transcriptomics (e.g., Visium) has been a cited growth catalyst but not yet margin-accretive.
  • No confirmed near-term earnings date in this context, but historical Q3 reporting typically lands in late October/early November.
  • High-beta profile (1.72) leaves TXG susceptible to sharp moves on sector or rate-driven biotech flows.

Context note: The headlines reflect a fundamentally challenged but strategically expanding story, which contrasts with the strongly bullish options flow observed in the embedded data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

  • Trailing EPS is -0.59; the company is not profitable on a trailing basis.
  • Trailing P/E: null; Forward P/E: null; PEG ratio: null — no standard valuation multiples available.
  • Market cap: $9,023,954,660.00; Shares outstanding: 130,291,000.00.
  • Dividend yield: 0.00%; no dividend distribution.
  • Beta: 1.72 (elevated systematic risk relative to market).
  • 52-week high: $102.81; 52-week low: $12.34 (wide range indicates prior extreme volatility).
  • Institutional ownership: 76.71% — moderately high institutional presence.
  • Average volume: 3,971,000.00; Historical volatility: 91.21% (very high).
  • Revenue growth, gross/operating/net margins, ROE, Debt/Equity, and FCF: all null in data.
  • Analyst target mean price and recommendation key: null — no consensus context.

Fundamental takeaway: Loss-making, no yield, no published margin or leverage metrics. This diverges from the bullish options sentiment, as fundamentals show no earnings support while options imply strong directional conviction.

Current Market Position

From the embedded data: Daily close on 2026-10-29 was $81.56 (formatted: $81.56). The minute bars show the stock opened 2026-10-29 at $82.13 and traded to $84.40 high / $80.08 low, closing $81.56. By 2026-10-30 12:30, the last bar shows price at $69.50, down sharply from prior day.

Key observational levels from daily history: 30-day range high $102.81 (2026-10-05), low $67.25 (2026-10-22). Recent daily close high $98.21 (2026-10-05), then a gap-down to $80.62 on 2026-10-06 with volume 7,969,475. Recent bounce to $83.95 on 2026-10-28, fading to $81.56 on 2026-10-29.

Intraday momentum (minute bars): 2026-10-29 09:30–09:50 trended up from $83.31 to $84.02; 2026-10-30 12:10–12:30 slid from $69.83 to $69.50 on rising volume (last bar 40,993), indicating late-session weakness.

Technical Analysis

Technical Indicators

Current Price
$81.56
SMA 5
$77.46
SMA 20
$77.22
SMA 50
$74.06
RSI 14
50.09
MACD
0.61
Signal
0.49
Histogram
0.12
BB Middle
$77.22
BB Upper
$92.53
BB Lower
$61.91
ATR 14
$6.14

SMA alignment: Price ($81.56) > SMA 5 ($77.46) > SMA 20 ($77.22) > SMA 50 ($74.06) — bullish stack, no bearish crossover. RSI at 50.09 shows neutral momentum, no overbought/oversold. MACD (0.61) above signal (0.49), histogram positive (0.12) = mild bullish bias. Bollinger: price inside bands, nearer upper half (mid $77.22). 30-day range: price $81.56 sits ~42% up from low ($67.25) to high ($102.81).

True Sentiment Analysis (Delta 40-60 Options)

From TXG_options_2026-10-30 data:

Call Dollar Volume: $1,364,530.00 (99.10%) Put Dollar Volume: $11,720.00 (0.90%) Total: $1,376,250.00

  • Call contracts: 2,385; Put contracts: 12 — extreme call skew.
  • Sentiment: Bullish
  • Pure directional conviction strongly favors calls (Delta 40-60 filtered).

Notable divergence: Technicals are neutral (RSI 50.09, no clear trend break), yet options flow is 99.1% call dollar volume. Option spread engine flagged: "Divergence detected between technical indicators and options sentiment."

Key Price Levels (Observational Only)

Support (30d low)
$67.25
Resistance (30d high)
$102.81
SMA 50
$74.06
BB Upper
$92.53
Recent Daily Low (10-22)
$67.25

Interactive charts load with JavaScript. This text is the crawlable summary.